Related references
Note: Only part of the references are listed.Fingolimod effects on left ventricular function in multiple sclerosis
Vittorio Racca et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Fingolimod effects on left ventricular function in multiple sclerosis
Vittorio Racca et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction
M. Germana Sanna et al.
MOLECULAR PHARMACOLOGY (2016)
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke A Pilot Trial
Zilong Zhu et al.
CIRCULATION (2015)
A NOVEL GRADUAL UP-TITRATION REGIMEN MITIGATES THE FIRST-DOSE EFFECTS OF PONESIMOD, A SELECTIVE S1P1 RECEPTOR MODULATOR
M. Hoch et al.
CLINICAL THERAPEUTICS (2015)
Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects
Kasra Shakeri-Nejad et al.
CLINICAL THERAPEUTICS (2015)
Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects
Shibadas Biswal et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Three Different Up-Titration Regimens of Ponesimod, an S1P1 Receptor Modulator, in Healthy Subjects
Michael W. Scherz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
Sonja Kroesser et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content Correction by Sphingosine-1-Phosphate-Loading
Katherine Sattler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects
Pierre-Eric Juif et al.
DRUGS IN R&D (2015)
Development and function of protective and pathologic memory CD4 T cells
Shafqat Ahrar Jaigirdar et al.
FRONTIERS IN IMMUNOLOGY (2015)
Effect of Ponesimod, a Selective S1P1 Receptor Modulator, on the QT Interval in Healthy Individuals
Matthias Hoch et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations
Daniele D'Ambrosio et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2015)
Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
Zi-Ye Song et al.
PLOS ONE (2015)
Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects
M. Hoch et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
The Immunosuppressant FTY720 Prolongs Survival in a Mouse Model of Diet-induced Coronary Atherosclerosis and Myocardial Infarction
Guanying Wang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Multiple-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponesimod, an S1P1 Receptor Modulator: Favorable Impact of Dose Up-Titration
P. Brossard et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator
Andreas Krause et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2014)
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial
Andrea Vaclavkova et al.
LANCET (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Effects of Ethnicity and Sex on the Pharmacokinetics and Pharmacodynamics of the Selective Sphingosine-1-Phosphate Receptor 1 Modulator Ponesimod: A Clinical Study in Japanese and Caucasian Subjects
Maribel Reyes et al.
PHARMACOLOGY (2014)
Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of GSK2018682, a Sphingosine-1-Phosphate Receptor Modulator, in Healthy Volunteers
Jianfeng Xu et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
Sphingosine kinase and sphingosine 1-phosphate in the heart: A decade of progress
Joel S. Karliner
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study
Patrick Brossard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects
Eric Legangneux et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
T. Komiya et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Systematic Review and Meta-Analysis of the Efficacy of Sphingosine-1-Phosphate (S1P) Receptor Agonist FTY720 (Fingolimod) in Animal Models of Stroke
Junfeng Liu et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
Daphne Y. S. Vogel et al.
JOURNAL OF NEUROINFLAMMATION (2013)
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
Aran Groves et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj et al.
LANCET NEUROLOGY (2013)
Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes
Sylvaine You et al.
PLOS ONE (2013)
FTY720 Ameliorates Acute Ischemic Stroke in Mice by Reducing Thrombo-Inflammation but Not by Direct Neuroprotection
Peter Kraft et al.
STROKE (2013)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Clinical Pharmacokinetics of Fingolimod
Olivier J. David et al.
CLINICAL PHARMACOKINETICS (2012)
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers
Robert Schmouder et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways
Markus Zollinger et al.
DRUG METABOLISM AND DISPOSITION (2011)
Memory/effector (CD45RBlo) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology
Masahito Kamanaka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
Luca Piali et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2011)
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M
Christina Christoffersen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The outs and the ins of sphingosine-1-phosphate in immunity
Sarah Spiegel et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning
Trung H. M. Pham et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Fingolimod is a potential novel therapy for multiple sclerosis
Orhan Aktas et al.
NATURE REVIEWS NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature
Jerold Chun et al.
PHARMACOLOGICAL REVIEWS (2010)
Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats
Yu Hasegawa et al.
STROKE (2010)
Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system
Yoh Takuwa et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2008)
The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects
John M. Kovarik et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The alliance of sphingosine-1-phosphate and its receptors in immunity
Juan Rivera et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Finding a way out: lymphocyte egress from lymphoid organs
Susan R. Schwab et al.
NATURE IMMUNOLOGY (2007)
HDL and its sphingosine-1-phosphate content in cardioprotection
Petra Keul et al.
HEART FAILURE REVIEWS (2007)
Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate
Rajita Pappu et al.
SCIENCE (2007)
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubipuitinylation and proteasomal degradation of the receptor
Myat Lin Oo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice
Petra Keul et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice
Jerzy-Roch Nofer et al.
CIRCULATION (2007)
FTY720 versus MMF with cyclosporine in de novo renal transplantation:: A 1-year, randomized controlled trial in Europe and Australasia
M. Salvadori et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
FTY720: Placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects
Robert Schmouder et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
FTY720 treatment of kidney transplant patients: A differential effect on B cells, naive T cells, memory T cells and NK cells
Leonard M. B. Vaessen et al.
TRANSPLANT IMMUNOLOGY (2006)
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients
SR Schwab et al.
SCIENCE (2005)
Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network
H Rosen et al.
NATURE REVIEWS IMMUNOLOGY (2005)
The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh
L Koyrakh et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit
CG Lo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects
JM Kovarik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Multiple-dose FTY720: Tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes
M Forrest et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate
MG Sanna et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study
BD Kahan et al.
TRANSPLANTATION (2003)
Sphingosine-1-phosphate: An enigmatic signalling lipid
S Spiegel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Chronic graft-versus-host disease: clinical manifestation and therapy
V Ratanatharathorn et al.
BONE MARROW TRANSPLANTATION (2001)
Sphingosine 1-phosphate: synthesis and release
Y Yatomi et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2001)
Characterization of a novel sphingosine 1-phosphate receptor, Edg-8
DS Im et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
